Effectiveness of EGFR treatment is impaired through an early adaptive response. TNF–JNK–Axl–ERK signaling contributes to this primary resistance to EGFR inhibition and might serve as novel target to improve EGFR inhibition.
References
Brennan, C.W. et al. Cell 155, 462–477 (2013).
Sugawa, N., Ekstrand, A.J., James, C.D. & Collins, V.P. Proc. Natl. Acad. Sci. USA 87, 8602–8606 (1990).
Reardon, D. A., Wen, P. Y. & Mellinghoff, I. K. Neuro Oncol. 16 (Suppl. 8), 7–13 (2014).
Guo, G. et al. Nat. Neurosci. 20, 1074–1084 (2017).
Jahani-Asl, A. et al. Nat. Neurosci. 19, 798–806 (2016).
Montgomery, R.B., Moscatello, D.K., Wong, A.J., Cooper, J.A. & Stahl, W.L. J. Biol. Chem. 270, 30562–30566 (1995).
Huang, P.H. et al. Proc. Natl. Acad. Sci. USA 104, 12867–12872 (2007).
Eskilsson, E. et al. Neuro Oncol. 18, 1644–1655 (2016).
Weller, M. et al. Neuro-oncol. 18 (Suppl. 6), 17–18 (2016).
Westphal, M. et al. Eur. J. Cancer 51, 522–532 (2015).
Sampson, J.H. et al. J. Clin. Oncol. 28, 4722–4729 (2010).
Akhavan, D. et al. Cancer Discov. 3, 534–547 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Warta, R., Herold-Mende, C. Helping EGFR inhibition to block cancer. Nat Neurosci 20, 1035–1037 (2017). https://doi.org/10.1038/nn.4605
Published:
Issue Date:
DOI: https://doi.org/10.1038/nn.4605
- Springer Nature America, Inc.